Vanhersecke, Lucile
Brunet, Maxime
Guégan, Jean-Philippe
Rey, Christophe
Bougouin, Antoine
Cousin, Sophie
Le Moulec, Sylvestre
Besse, Benjamin
Loriot, Yohann
Larroquette, Mathieu
Soubeyran, Isabelle
Toulmonde, Maud
Roubaud, Guilhem
Pernot, Simon
Cabart, Mathilde http://orcid.org/0000-0003-3132-0069
Chomy, François
Lefevre, Corentin
Bourcier, Kevin
Kind, Michèle
Giglioli, Ilenia
Sautès-Fridman, Catherine http://orcid.org/0000-0003-1735-8722
Velasco, Valérie
Courgeon, Félicie
Oflazoglu, Ezoglin
Savina, Ariel
Marabelle, Aurélien http://orcid.org/0000-0002-5816-3019
Soria, Jean-Charles
Bellera, Carine
Sofeu, Casimir
Bessede, Alban
Fridman, Wolf H. http://orcid.org/0000-0002-1332-0973
Le Loarer, François http://orcid.org/0000-0001-8582-9819
Italiano, Antoine http://orcid.org/0000-0002-8540-5351
Funding for this research was provided by:
AstraZeneca (AZ TLS)
Article History
Received: 16 January 2021
Accepted: 8 June 2021
First Online: 12 August 2021
Competing interests
: A. Bessede, J.-P.G. and C.R. are employees of ImmuSmol/Explicyte. E.O. and A.S. are employees of AstraZeneca. A.I. received research grants from AstraZeneca, Bayer, Bristol Myers Squibb, Chugai, Merck, MSD, PharmaMar, Novartis and Roche and received personal fees from Epizyme, Bayer, Lilly, Roche and SpringWorks. B.B. received grants from AstraZeneca, Pfizer, Eli Lilly, Onxeo, Bristol Myers Squibb, Inivata, AbbVie, Amgen, Blueprint Medicines, Celgene, GlaxoSmithKline, Ignyta, Ipsen, Merck KGaA, MSD Oncology, Nektar, PharmaMar, Sanofi, Spectrum Pharmaceuticals, Takeda, Tiziana Therapeutics, Cristal Therapeutics, Daiichi Sankyo, Janssen Oncology, OSE Immunotherapeutics, BeiGene, Boehringer Ingelheim, Genentech, Servier and Tolero Pharmaceuticals. Y.L. received grants from Janssen, Sanofi and MSD, personal fees from Janssen, Sanofi, Astellas, Roche, AstraZeneca, Bristol Myers Squibb, Seattle Genetics, MSD, Clovis, Incyte and Pfizer and non-financial support from Astellas, Roche, AstraZeneca, Bristol Myers Squibb, Seattle Genetics and MSD. A.M. received research grants from Merus, Bristol Myers Squibb, Boehringer Ingelheim, Transgene and MSD and personal fees from Bristol Myers Squibb, AstraZeneca, MedImmune, Oncovir and Merieux. J.-C.S. received consultancy fees from AstraZeneca, Astex, Clovis, GlaxoSmithKline, GamaMabs, Lilly, MSD, Mission Therapeutics, Merus, Pfizer, PharmaMar, Pierre Fabre, Roche/Genentech, Sanofi, Servier, Symphogen and Takeda. L.V., M.B., S.C., S.L.M., M.L., I.S., M.T., G.R., S.P., M.C., F.C., C.L., K.B., M.K., I.G., C.S.-F., V.V., F.C., W.H.F. and F.L.L. declare no competing interests.